All In Biotech

Drug Trial Radar · NCT00370032

Study to Assess the Effect Of Alosetron On Mucosal Blood Flow

A Randomize, Placebo-controlled, Crossover Study to Measure the Effect of Alosetron on Mucosal Blood Flow in Female Healthy Volunteers and Diarrhea-predominant IBS Subjects

Last checked: Nov 19, 2026Latest source record: May 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

49

Actual

Start

Dec 2006

Primary completion

Dec 2007

Study completion Dec 2007

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 30, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will look at colonic mucosal blood flow in subjects who have taken alosetron vs placebo and healthy volunteers vs diarrhea-predominant Irritable Bowel Syndrome (d-IBS) patients.

Conditions

  • Irritable Colon

Interventions

  • alosetronDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Left Colon Mucosal Blood Flow (MBF)Time frame: Day 6 after each treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.